Skip to main content
main-content

25-09-2017 | ESMO 2017 | Video

Durvalumab: A new option for stage III NSCLC patients?

Study co-author Davey Daniel reviews the findings of the phase III PACIFIC trial investigating durvalumab in patients with locally advanced, unresectable NSCLC.